Nevertheless, cells derived from the untreated tumor mass, cultured, and treated ex vivo with SR59230A, confirmed activation of the differentiation process in the TME of the β3-AR antagonist treated mice (Supplementary Figure S1b). The gene discussed is ADRB3; the disease is neoplasm.